Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Advisors LLC

Neither a doctor nor a teaching hospital

Research payments

$604,746

137 payments

Through program year 2025, Clinical Research Advisors LLC is reported as receiving $604,746 in research payments, across 137 payments.

By program year

2 rows
Year Kind Amount Payments
2025 Research $574,832 135
2024 Research $29,914 2

Breakdown

Who paid Research payments · program years 2024–2025
  1. Aveo Pharmaceuticals, Inc. $207,282 98 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $194,273 24 payments
  3. Coherus Biosciences Inc. $129,331 9 payments
  4. AbbVie, Inc. $40,860 5 payments
  5. Puma Biotechnology, Inc. $33,000 1 payment
Studies the money was for Research payments · program years 2024–2025
  1. A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels $207,282 98 payments
  2. An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) $194,273 24 payments
  3. Chs38802 $129,331 9 payments
  4. Ali-1201 $33,000 1 payment
  5. Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) $29,588 1 payment
  6. Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) $7,350 1 payment
  7. M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) $3,500 1 payment
  8. M23-362 Ph2 Epcoritamab RR DLBCL and FL Outpatient Study $326 1 payment
  9. A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting $96 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record